Corresponding Author: Francis S. Collins, MD, PhD, Office of the Director, National Institutes of Health, One Center Dr, Bldg 1, Room 126, Bethesda, MD 20892 (collinsf@od.nih.gov).
Published Online: May 18, 2020. doi:10.1001/jama.2020.8920
Conflict of Interest Disclosures: None reported.
Additional Contributions: We would like to acknowledge Ashley Parker, Rebecca Kolberg, and David Wholley for their help in the preparation of this article. We would also like to thank the leadership of AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Evotec, Gilead, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir. We also thank multiple NIH institutes (especially NIAID), the FDA, BARDA, CDC, the European Medicines Agency, the Department of Defense, the VA, and the Foundation for NIH for their commitment in engaging in this unprecedented partnership.
6.Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) portal. National Institutes of Health. Accessed May 15, 2020.
https://www.nih.gov/ACTIV